Rajiv Malik

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Ranbaxy Laboratories Ltd. operated as an integrated international pharmaceutical organization. The company engaged in the marketing, production and distribution of pharmaceutical products. It manufactured and markets molecules and their combinations to therapies, which include anti-infective, cardiovascular, pain management, central nervous system, gastrointestinal, respiratory, dermatology, orthopedics, nutritionals and urology. The company was founded on June 16, 1961 and headquartered in Gurgaon, India.

Mylan Laboratories Ltd. manufactures and supplies active pharmaceutical ingredients. The firm operates through two segments: Pharmaceuticals and Medical Supplies. It manufactures and supplies generic and branded generic formulations to various markets, including North America, Europe and Asia Pacific. Mylan Laboratories was founded on November 29, 1984 and is headquartered in Hyderabad, India.

Mylan Pharmaceuticals, Inc. develops and manufactures generic prescription products. Its product includes tablets, Fosamax, Sectral, Xanax, capsules, liquids, and transdermal patches. The company was founded in 1961 and is headquartered in Morgantown, WV.

ANG Industries Ltd. engaged in the manufacture and sale of automotive components and parts. The company was founded on July 24, 1991 and is headquartered in New Delhi, India.

Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria.